{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:06:37Z","timestamp":1768511197899,"version":"3.49.0"},"posted":{"date-parts":[[2024,4,9]]},"group-title":"Neuroscience","reference-count":89,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Tauopathies, including Alzheimer\u2019s disease (AD) and Frontotemporal Dementia (FTD), are histopathologically defined by the aggregation of hyperphosphorylated pathological tau (pTau) as neurofibrillary tangles in the brain. Site-specific phosphorylation of tau occurs early in the disease process and correlates with progressive cognitive decline, thus serving as targetable pathological epitopes for immunotherapeutic development. Previously, we developed a vaccine (Q\u03b2-pT181) displaying phosphorylated Thr181 tau peptides on the surface of a Q\u03b2 bacteriophage virus-like particle (VLP) that induced robust antibody responses, cleared pathological tau, and rescued memory deficits in a transgenic mouse model of tauopathy. Here we report the characterization and comparison of two additional Q\u03b2 VLP-based vaccines targeting the dual phosphorylation sites Ser199\/Ser202 (Q\u03b2-AT8) and Ser396\/Ser404 (Q\u03b2-PHF1). Both Q\u03b2-AT8 and Q\u03b2-PHF1 vaccines elicited high-titer antibody responses against their pTau epitopes. However, only Q\u03b2-PHF1 rescued cognitive deficits, reduced soluble and insoluble pathological tau, and reactive microgliosis in a 4-month rTg4510 model of FTD. Both sera from Q\u03b2-AT8 and Q\u03b2-PHF1 vaccinated mice were specifically reactive to tau pathology in human AD post-mortem brain sections. These studies further support the use of VLP-based immunotherapies to target pTau in AD and related tauopathies and provide potential insight into the clinical efficacy of various pTau epitopes in the development of immunotherapeutics.<\/jats:p>","DOI":"10.1101\/2024.04.05.588338","type":"posted-content","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T21:50:12Z","timestamp":1712699412000},"source":"Crossref","is-referenced-by-count":1,"title":["Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396\/Ser404 (PHF1) site outperforms phosphorylated S199\/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6184-2058","authenticated-orcid":false,"given":"Jonathan","family":"Hulse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-1027","authenticated-orcid":false,"given":"Nicole","family":"Maphis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-7513","authenticated-orcid":false,"given":"Julianne","family":"Peabody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5712-4739","authenticated-orcid":false,"given":"Bryce","family":"Chackerian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6064-8106","authenticated-orcid":false,"given":"Kiran","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024041107351204000_2024.04.05.588338v1.1","doi-asserted-by":"publisher","DOI":"10.1002\/ca.980080612"},{"key":"2024041107351204000_2024.04.05.588338v1.2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","year":"2019","journal-title":"Molecular Neurodegeneration"},{"key":"2024041107351204000_2024.04.05.588338v1.3","doi-asserted-by":"publisher","DOI":"10.2174\/156720510793611592"},{"key":"2024041107351204000_2024.04.05.588338v1.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.121119298"},{"key":"2024041107351204000_2024.04.05.588338v1.5","first-page":"346","article-title":"Post-translational modifications of tau protein","volume":"107","year":"2006","journal-title":"Bratisl Lek Listy"},{"key":"2024041107351204000_2024.04.05.588338v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(82)90155-1"},{"key":"2024041107351204000_2024.04.05.588338v1.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.3.631"},{"key":"2024041107351204000_2024.04.05.588338v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02049-x"},{"key":"2024041107351204000_2024.04.05.588338v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2017.03.002"},{"key":"2024041107351204000_2024.04.05.588338v1.10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5732"},{"key":"2024041107351204000_2024.04.05.588338v1.11","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","article-title":"Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease","volume":"11","year":"2020","journal-title":"Nat Commun"},{"key":"2024041107351204000_2024.04.05.588338v1.12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-neuro-072116-031153"},{"key":"2024041107351204000_2024.04.05.588338v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2786"},{"key":"2024041107351204000_2024.04.05.588338v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4443"},{"key":"2024041107351204000_2024.04.05.588338v1.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031302"},{"key":"2024041107351204000_2024.04.05.588338v1.16","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2642-12.2013"},{"key":"2024041107351204000_2024.04.05.588338v1.17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301175110"},{"key":"2024041107351204000_2024.04.05.588338v1.18","doi-asserted-by":"crossref","unstructured":"DeVos, S. L. et al. Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer\u2019s Disease Brain. Front. Neurosci. 12, (2018).","DOI":"10.3389\/fnins.2018.00267"},{"key":"2024041107351204000_2024.04.05.588338v1.19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s12031-023-02143-w","article-title":"Spreading of Tau Protein Does Not Depend on Aggregation Propensity","volume":"73","year":"2023","journal-title":"J Mol Neurosci"},{"key":"2024041107351204000_2024.04.05.588338v1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2024041107351204000_2024.04.05.588338v1.21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","year":"2023","journal-title":"JAMA"},{"key":"2024041107351204000_2024.04.05.588338v1.22","first-page":"36","article-title":"Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design","volume":"8","year":"2019","journal-title":"Manufacture, and Formulation. Antibodies (Basel)"},{"key":"2024041107351204000_2024.04.05.588338v1.23","doi-asserted-by":"crossref","first-page":"100657","DOI":"10.1016\/j.lanepe.2023.100657","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint","volume":"29","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2024041107351204000_2024.04.05.588338v1.24","first-page":"362","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2024041107351204000_2024.04.05.588338v1.25","doi-asserted-by":"crossref","unstructured":"Mena Lora, A. J. , et al. Feasibility and impact of a monoclonal antibody infusion program in reaching vulnerable underserved communities. Infect Control Hosp Epidemiol 44, 1690\u20131692.","DOI":"10.1017\/ice.2023.25"},{"key":"2024041107351204000_2024.04.05.588338v1.26","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jama.2023.11704","article-title":"Donanemab for Alzheimer Disease\u2014Who Benefits and Who Is Harmed?","volume":"330","year":"2023","journal-title":"JAMA"},{"key":"2024041107351204000_2024.04.05.588338v1.27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","year":"2021","journal-title":"Journal of Nanobiotechnology"},{"key":"2024041107351204000_2024.04.05.588338v1.28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer\u2019s disease","volume":"7","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"2024041107351204000_2024.04.05.588338v1.29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-019-0118-4","article-title":"Q\u00df Virus-like particle-based vaccine induces robust immunity and protects against tauopathy","volume":"4","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2024041107351204000_2024.04.05.588338v1.30","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.3.381"},{"key":"2024041107351204000_2024.04.05.588338v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/nri2868"},{"key":"2024041107351204000_2024.04.05.588338v1.32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-061008-103129"},{"key":"2024041107351204000_2024.04.05.588338v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.029"},{"key":"2024041107351204000_2024.04.05.588338v1.34","doi-asserted-by":"publisher","DOI":"10.1007\/BF00293315"},{"key":"2024041107351204000_2024.04.05.588338v1.35","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e318232a379"},{"key":"2024041107351204000_2024.04.05.588338v1.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1632-3"},{"key":"2024041107351204000_2024.04.05.588338v1.37","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12084"},{"key":"2024041107351204000_2024.04.05.588338v1.38","doi-asserted-by":"publisher","DOI":"10.1007\/s004010100423"},{"key":"2024041107351204000_2024.04.05.588338v1.39","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-199851"},{"key":"2024041107351204000_2024.04.05.588338v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.04.187"},{"key":"2024041107351204000_2024.04.05.588338v1.41","doi-asserted-by":"publisher","DOI":"10.1002\/prot.24988"},{"key":"2024041107351204000_2024.04.05.588338v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)11484-E"},{"key":"2024041107351204000_2024.04.05.588338v1.43","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490390607"},{"key":"2024041107351204000_2024.04.05.588338v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.01.006"},{"key":"2024041107351204000_2024.04.05.588338v1.45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40478-018-0557-6","article-title":"Phosphorylation of different tau sites during progression of Alzheimer\u2019s disease","volume":"6","year":"2018","journal-title":"Acta Neuropathologica Communications"},{"key":"2024041107351204000_2024.04.05.588338v1.46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00401-023-02659-w","article-title":"CSF p-tau205: a biomarker of tau pathology in Alzheimer\u2019s disease","volume":"147","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"Pt 21","key":"2024041107351204000_2024.04.05.588338v1.47","first-page":"3737","article-title":"C-terminal inhibition of tau assembly in vitro and in Alzheimer\u2019s disease","volume":"113","year":"2000","journal-title":"J Cell Sci"},{"key":"2024041107351204000_2024.04.05.588338v1.48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.trci.2018.09.005","article-title":"Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau","volume":"4","year":"2018","journal-title":"Alzheimers Dement (N Y"},{"key":"2024041107351204000_2024.04.05.588338v1.49","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1038\/s41598-018-24276-4","article-title":"Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein","volume":"8","year":"2018","journal-title":"Sci Rep"},{"key":"2024041107351204000_2024.04.05.588338v1.50","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3542-15.2016"},{"key":"2024041107351204000_2024.04.05.588338v1.51","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M805300200"},{"key":"2024041107351204000_2024.04.05.588338v1.52","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-006-0127-z"},{"key":"2024041107351204000_2024.04.05.588338v1.53","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3279-05.2005"},{"key":"2024041107351204000_2024.04.05.588338v1.54","doi-asserted-by":"publisher","DOI":"10.1126\/science.1113694"},{"key":"2024041107351204000_2024.04.05.588338v1.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.044"},{"key":"2024041107351204000_2024.04.05.588338v1.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.059"},{"key":"2024041107351204000_2024.04.05.588338v1.57","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.050840"},{"key":"2024041107351204000_2024.04.05.588338v1.58","doi-asserted-by":"publisher","DOI":"10.1101\/gr.233866.117"},{"key":"2024041107351204000_2024.04.05.588338v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10428-1"},{"key":"2024041107351204000_2024.04.05.588338v1.60","doi-asserted-by":"publisher","DOI":"10.1007\/s10339-011-0430-z"},{"key":"2024041107351204000_2024.04.05.588338v1.61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.15.5827"},{"key":"2024041107351204000_2024.04.05.588338v1.62","doi-asserted-by":"publisher","DOI":"10.1038\/197192b0"},{"key":"2024041107351204000_2024.04.05.588338v1.63","doi-asserted-by":"publisher","DOI":"10.3109\/10520298809107184"},{"key":"2024041107351204000_2024.04.05.588338v1.64","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-007-0200-2"},{"key":"2024041107351204000_2024.04.05.588338v1.65","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01315-6"},{"key":"2024041107351204000_2024.04.05.588338v1.66","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000911"},{"key":"2024041107351204000_2024.04.05.588338v1.67","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv081"},{"key":"2024041107351204000_2024.04.05.588338v1.68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13024-017-0184-x","article-title":"Late onset Alzheimer\u2019s disease genetics implicates microglial pathways in disease risk","volume":"12","year":"2017","journal-title":"Molecular Neurodegeneration"},{"key":"2024041107351204000_2024.04.05.588338v1.69","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s43587-023-00424-y","article-title":"Human microglia show unique transcriptional changes in Alzheimer\u2019s disease","volume":"3","year":"2023","journal-title":"Nat Aging"},{"key":"2024041107351204000_2024.04.05.588338v1.70","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0358-2"},{"key":"2024041107351204000_2024.04.05.588338v1.71","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-020-0599-5"},{"key":"2024041107351204000_2024.04.05.588338v1.72","doi-asserted-by":"crossref","first-page":"17377","DOI":"10.3390\/ijms242417377","article-title":"Minding the Gap: Exploring Neuroinflammatory and Microglial Sex Differences in Alzheimer\u2019s Disease","volume":"24","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024041107351204000_2024.04.05.588338v1.73","doi-asserted-by":"crossref","first-page":"109720","DOI":"10.1016\/j.celrep.2021.109720","article-title":"Proteopathic tau primes and activates interleukin-1\u03b2 via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway","volume":"36","year":"2021","journal-title":"Cell Rep"},{"key":"2024041107351204000_2024.04.05.588338v1.74","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00198"},{"key":"2024041107351204000_2024.04.05.588338v1.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2010.08.023"},{"key":"2024041107351204000_2024.04.05.588338v1.76","doi-asserted-by":"crossref","unstructured":"Maphis, N. et al. Loss of tau rescues inflammation-mediated neurodegeneration. Front. Neurosci. 9, (2015).","DOI":"10.3389\/fnins.2015.00196"},{"key":"2024041107351204000_2024.04.05.588338v1.77","doi-asserted-by":"crossref","unstructured":"Hulse, J. & Bhaskar, K . Crosstalk Between the NLRP3 Inflammasome\/ASC Speck and Amyloid Protein Aggregates Drives Disease Progression in Alzheimer\u2019s and Parkinson\u2019s Disease. Frontiers in Molecular Neuroscience 15, (2022).","DOI":"10.3389\/fnmol.2022.805169"},{"key":"2024041107351204000_2024.04.05.588338v1.78","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1769-z"},{"key":"2024041107351204000_2024.04.05.588338v1.79","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201900439"},{"key":"2024041107351204000_2024.04.05.588338v1.80","doi-asserted-by":"publisher","DOI":"10.1038\/nature11729"},{"key":"2024041107351204000_2024.04.05.588338v1.81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29552-6"},{"key":"2024041107351204000_2024.04.05.588338v1.82","doi-asserted-by":"publisher","DOI":"10.1038\/nature23002"},{"key":"2024041107351204000_2024.04.05.588338v1.83","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1914-z"},{"key":"2024041107351204000_2024.04.05.588338v1.84","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/j.1460-2075.1992.tb05204.x","article-title":"The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region","volume":"11","year":"1992","journal-title":"EMBO J"},{"key":"2024041107351204000_2024.04.05.588338v1.85","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505895200"},{"key":"2024041107351204000_2024.04.05.588338v1.86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/vaccines4010003","article-title":"Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7","volume":"4","year":"2016","journal-title":"Vaccines"},{"key":"2024041107351204000_2024.04.05.588338v1.87","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(84)90007-4"},{"key":"2024041107351204000_2024.04.05.588338v1.88","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.116"},{"key":"2024041107351204000_2024.04.05.588338v1.89","first-page":"1","article-title":"Silver staining of Alzheimer\u2019s neurofibrillary changes by means of physical development","volume":"19","year":"1971","journal-title":"Acta Morphol Acad Sci Hung"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.04.05.588338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:15:28Z","timestamp":1768457728000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.04.05.588338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":89,"URL":"https:\/\/doi.org\/10.1101\/2024.04.05.588338","relation":{},"subject":[],"published":{"date-parts":[[2024,4,9]]},"subtype":"preprint"}}